Researchers at the Sao Jose do Rio Preto Medical School (FAMERP) in Brazil, performed molecular tests on blood samples from 800 people treated as suspected dengue patients between January and August 2016.
The initial diagnosis, based on clinical symptoms and serological tests, was confirmed in only 400 samples.
More than 100 of the cases analysed were positive for Zika virus, and the virus that causes chikungunya fever was identified in one of the samples.
None of the three arboviruses transmitted by Aedes aegypti was found in the remaining samples (almost 300).
"These results suggest the classic division usually made between symptoms - associating conjunctivitis with Zika and joint pain with chikungunya, for example - is only for classroom use. In practice, the symptoms can't be separated like that," said Mauricio Lacerda Nogueira, who led the study.
"It's also practically impossible to distinguish between the three arboviruses with the serological tests currently used on a routine basis by laboratories and emergency services," Nogueira said.
Although new serological methods capable of distinguishing accurately between Zika and dengue antibodies have been developed, so far they are used only in academic research, he said.
The World Health Organisation (WHO) recommends that all cases with an uncertain diagnosis should be treated as dengue because the risk of death from dengue is higher than from Zika and chikungunya.
False-positive results for dengue do not jeopardise treatment of patients but generate unnecessary costs for the health service, according to Nogueira.
"Rest and oral rehydration at home is usually sufficient for people with Zika, except pregnant women," he said.
For Nogueira, false positives are, above all, a cause for concern because they create uncertainty about official epidemiological statistics.
Uncertainty about the statistics tends to undermine the effectiveness of public policy to prevent and treat diseases, Nogueira added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
